Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JACDS May Violate Antimonopoly Act by Calling on Members Not to Offer Point Cards
March 21, 2011
- MSD K.K. Submits NDA for Caspofungin
March 21, 2011
- Nichiyakubo to Call For Improvement of Drug Substance Import System
March 21, 2011
- Eli Lilly's Gemzar Receives Add'l Indication for Ovarian Cancer
March 21, 2011
- Astellas to Challenge New Field of Regenerative Medicine
March 21, 2011
- Herceptin Approved for Gastric Cancer as Add'l Indication
March 21, 2011
- Shionogi Terminates Development of S-2367 for Obesity Drug in the US, Europe
March 21, 2011
- Stiripentol Designated as Orphan Drug
March 21, 2011
- Daiichi Sankyo to Invite Joint Drug Discovery Projects for Open Innovation
March 21, 2011
- Janssen: Stelara for Psoriasis
March 21, 2011
- Eisai Ties Up with Epizyme for Cancer Treatments
March 21, 2011
- Sales of Ethical Drugs Up 3.9% in January: Crecon Research & Consulting
March 21, 2011
- Dr Lechleiter of Eli Lilly Calls For Full Introduction of Premium for Development of New Drugs
March 21, 2011
- GSK: Arixtra for Treatment of Acute DVT, Acute PTE
March 21, 2011
- NIBIO Opens Toxicogenomics DB
March 21, 2011
- Yakult Licenses Perifosine from Aeterna Zentaris
March 21, 2011
- Kyowa Kirin Begins PIII for Pegfilgrastim
March 21, 2011
- Pfizer to Enhance Focus on Infectious Diseases
March 21, 2011
- Janssen Begins PIII Trial of Concerta for AD/HD in Adults
March 21, 2011
- Analysts Question Kyowa Kirin's Acquisition of ProStrakan
March 21, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…